However, several studies have highlighted the significant role of neoadjuvant endocrine therapy (NET) as an alternative option to chemotherapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancers (BC), especially in the postmenopausal setting [3,4,5]. Here, ERBB2 is linked to breast cancer.